Literature DB >> 30770496

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Sherene Loi, Sathana Dushyanthen, Paul A Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L Rimm, Jennifer M Giltnane, Monica V Estrada, Violeta Sánchez, Melinda E Sanders, Rebecca S Cook, Mark A Pilkinton, Simon A Mallal, Kai Wang, Vincent A Miller, Phil J Stephens, Roman Yelensky, Franco D Doimi, Henry Gómez, Sergey V Ryzhov, Phillip K Darcy, Carlos L Arteaga, Justin M Balko.   

Abstract

Entities:  

Year:  2019        PMID： 30770496     DOI： 10.1158/1078-0432.CCR-18-4264

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

Review 1.  Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer.

Authors:  Wenjie Zhao; Jinhua Liu; Yaqun Li; Zichao Chen; Dongmei Qi; Zhen Zhang
Journal:  Front Pharmacol       Date:  2021-12-03       Impact factor: 5.810

Review 2.  Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.

Authors:  Samia S Messeha; Najla O Zarmouh; Karam F A Soliman
Journal:  Nutrients       Date:  2021-05-19       Impact factor: 5.717

Review 3.  A2B Adenosine Receptor and Cancer.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Int J Mol Sci       Date:  2019-10-17       Impact factor: 5.923

Review 4.  A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.

Authors:  Jie Zhang; Zhujiang Dai; Cheng Yan; Wenjie Zhang; Daorong Wang; Dong Tang
Journal:  Clin Transl Oncol       Date:  2021-06-14       Impact factor: 3.405
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.